Cover Image

Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system

Background: Given that the fight against coronavirus disease 2019 (COVID-19) is not over, we aimed to explore the occurrence of agranulocytosis and infectious complications in patients with and without COVID-19 following immunoregulatory therapy based on real-world data.Methods: This was a retrospec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chunyan Wei (Author), Wanhong Yin (Author), Tingting Hu (Author), Jingyi Zhang (Author), Huifang Dan (Author), Bin Wu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis
by: Aidou Jiang, et al.
Published: (2024)

Shuxie-1 Decoction Alleviated CUMS -Induced Liver Injury via IL-6/JAK2/STAT3 Signaling
by: Mengting Zhang, et al.
Published: (2022)

Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
by: Xiangyu Sun, et al.
Published: (2024)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
by: Wenting Zhang, et al.
Published: (2024)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system
by: Jingyi Zhang, et al.
Published: (2024)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
by: Huqun Li, et al.
Published: (2024)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022)

The roles and patterns of critical care pharmacists: a literature review and practical operation model in China
by: Chunyan Wei, et al.
Published: (2024)

Cost-effectiveness analysis of pharmaceutical care in adult critically ill patients: based on a prospective cohort study
by: Chunyan Wei, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios
by: Daniel N. A. Ankrah, et al.
Published: (2018)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
by: Shupeng Zou, et al.
Published: (2024)

Drug-Induced Neutropenia and Agranulocytosis
by: O. D. Ostroumova, et al.
Published: (2020)

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)
by: Jie Zhou, et al.
Published: (2024)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
by: Zheng Zhang, et al.
Published: (2024)

Drug-induced agranulocytosis: Case series
by: Čolović Nataša R., et al.
Published: (2018)

Agranulocytosis: a rare complication of the thionamides
by: Hawa Juma El-Shareif
Published: (2023)

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
by: Yiwen Wang, et al.
Published: (2024)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
by: Wenqiang Kong, et al.
Published: (2023)

Dapsone-induced agranulocytosis in patients with Hansen's disease
by: Tania Rita Moreno de Oliveira Fernandes, et al.
Published: (2017)

Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous
by: Bernd Rattay, et al.
Published: (2021)

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis
by: Shusuke Numata, et al.
Published: (2018)

Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database.
by: Pamella Modingam, et al.
Published: (2024)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024)

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
by: Kaixuan Wang, et al.
Published: (2024)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2022)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024)

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
by: Jinger Lin, et al.
Published: (2024)

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS)
by: Victor Pera, et al.
Published: (2023)